Jonathan Spicer

24PUBLICATIONS
214CO-AUTHORS
Predictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Cancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jan 08, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.

Mariano Provencio, Mark M Awad, Jonathan D Spicer

|Dec 03, 2025
Architecture of the neutrophil compartment.

Daniela Cerezo-Wallis, Andrea Rubio-Ponce, Mathis Richter

|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.

Tina Cascone, Laura Bonanno, Florian Guisier

|Feb 20, 2025
Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers 2024, 16, 2492.

Nicolas Girard, Mariam Besada, Basia Rogula

|Feb 05, 2025
Spatially mapping the tumour immune microenvironments of non-small cell lung cancer.

Lysanne Desharnais, Mark Sorin, Morteza Rezanejad

|Jan 08, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.

Mark M Awad, Patrick M Forde, Nicolas Girard

Pageof 4

Frequent Collaborators

6 joint publications

Patrick M Forde

5 joint publications

Logan A Walsh

4 joint publications

Roni Rayes

4 joint publications

Sophie Camilleri-Broet